Browsing by Author "García-De La Torre I."

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • No Thumbnail Available
    ItemMetadata only
    Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: results from the COVID-19 Vaccination in Autoimmune Disease (COVAD) study
    (2024-01-01) Palazzo L.; Lindblom J.; Kihlgren Olsson E.; Nikiphorou E.; Wincup C.; Saha S.; Shaharir S.S.; Katchamart W.; Akarawatcharangura Goo P.; Traboco L.; Chen Y.M.; Lilleker J.B.; Nune A.; Pauling J.D.; Agarwal V.; Dzifa D.; Toro Gutiérrez C.E.; Caballero-Uribe C.V.; Chinoy H.; Zimba O.; Fonseca J.E.; Pereira Silva J.A.; Rojas Zuleta W.G.; Shaharir S.S.; Landon-Cardinal O.; Hudson M.; Srivastav N.; Needham M.; Limaye V.; Langguth D.; Nagy-Vincze M.; Meyer A.; Campagne J.; Maurier F.; Giannini M.; Hoff L.S.; Hmamouchi I.; Gheita T.A.; Aharonov O.; Gromova M.A.; Tomaras S.; Knitza J.; Kaneko Y.; Kimura N.; Sato S.; Nakashima R.; Yoshida A.; Kuwana M.; Gonzalez R.A.; Gil-Vila A.; Prieto-González S.; Loarce-Martos J.; García-De La Torre I.; Serrano J.R.; Tehozol E.A.Z.; Wibowo S.A.K.; Traboco L.; Milchert M.; Venerito V.; Danielli M.G.; De Angelis R.; Orsolini G.; Sainaghi P.P.; Franceschini F.; Quartuccio L.; Sebastiani M.; Fusaro E.; Sebastiani G.D.; Bocci E.B.; Parisi S.; Govoni M.; Fabiola A.; Sambataro G.; Del Papa N.; Cavagna L.; Wincup C.; Pauling J.D.; Chatterjee T.; Makol A.; Kim M.; Cansu D.Ü.; Kardes S.; Chandwar K.; Pandey A.K.R.; Shukla A.; Bommakanti K.T.; Asranna A.; Shenoy P.; Mathew A.J.; Chowdhury A.C.; Goswami R.P.; Phatak S.; Ajmani S.; Patro P.S.; Kavadichanda C.G.; Gupta V.; M M.M.; Sharma A.; Pilania R.K.; Pandya S.C.; Palazzo L.; Mahidol University
    Objective: To determine the occurrence of breakthrough COVID-19 infections (BIs) in patients with systemic lupus erythematosus (SLE) compared with patients with other rheumatic autoimmune diseases (rAIDs), patients with non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HCs). Methods: The study was based on data from 7035 fully vaccinated respondents to the online COVAD questionnaire with SLE (N = 852), rAIDs (N = 3098), or nrAIDs (N = 414), and HCs (N = 2671). BI was defined as COVID-19 infection occurring in individuals vaccinated with ≥ 2 doses (or 1 dose of J&J) ≥ 14 days after vaccination and not after 6 months since the last vaccine dose. Data were analysed using linear and logistic regression models. Results: A total of 91/852 (10.7%) SLE patients reported at least one BI. The frequency of BIs in SLE patients was comparable to that among HCs (277/2671; p = 0.847) and patients with nrAID (39/414; p = 0.552) but higher than that among patients with other rAIDs (235/3098; p = 0.005). No demographic factors or treatments were associated with BIs in SLE patients (p ≥ 0.05 for all). Joint pain was more frequent in SLE patients than in HCs (odds ratio [OR]: 3.38; 95% confidence interval [CI]: 1.89–6.04; p < 0.001) or nrAID patients (OR: 2.44; 95% CI: 1.04–5.75; p = 0.041). Patient with SLE did not report a higher frequency of hospitalisation or need for advanced treatment for COVID-19 infection compared with disease controls and HCs, respectively. Conclusion: COVID-19 vaccination conferred similar protection against COVID-19 infection in terms of frequency and severity in patients with SLE to that reported by healthy individuals.
  • No Thumbnail Available
    ItemMetadata only
    Flares in IIMs and the timeline following COVID-19 vaccination: a combined analysis of the COVAD-1 and -2 surveys
    (2024-01-01) Naveen R.; Sen P.; Griger Z.; Day J.; Joshi M.; Nune A.; Nikiphorou E.; Saha S.; Tan A.L.; Shinjo S.K.; Ziade N.; Velikova T.; Milchert M.; Jagtap K.; Parodis I.; Gracia-Ramos A.E.; Cavagna L.; Kuwana M.; Knitza J.; Chen Y.M.; Makol A.; Agarwal V.; Patel A.; Pauling J.D.; Wincup C.; Barman B.; Zamora Tehozol E.A.; Rojas Serrano J.; García-De La Torre I.; Colunga-Pedraza I.J.; Merayo-Chalico J.; Chibuzo O.C.; Katchamart W.; Akarawatcharangura Goo P.; Shumnalieva R.; Hoff L.S.; El Kibbi L.; Halabi H.; Vaidya B.; Shaharir S.S.; Hasan A.T.M.T.; Dey D.; Toro Gutiérrez C.E.; Caballero-Uribe C.V.; Lilleker J.B.; Salim B.; Gheita T.; Chatterjee T.; Distler O.; Saavedra M.A.; Chinoy H.; Agarwal V.; Aggarwal R.; Gupta L.; Kardes S.; Andreoli L.; Lini D.; Screiber K.; Vince M.N.; Singh Y.P.; Ranjan R.; Jain A.; Pandya S.C.; Pilania R.K.; Sharma A.; Manesh Manoj M.; Gupta V.; Kavadichanda C.G.; Patro P.S.; Ajmani S.; Phatak S.; Goswami R.P.; Chowdhury A.C.; Mathew A.J.; Shenoy P.; Asranna A.; Bommakanti K.T.; Shukla A.; Pande A.R.; Chandwar K.; Ghodke A.; Boro H.; Fazal Z.Z.; Cansu D.Ü.; Ylldlrlm R.; Gasparyan A.Y.; Del Papa N.; Sambataro G.; Fabiola A.; Govoni M.; Parisi S.; Bocci E.B.; Sebastiani G.D.; Fusaro E.; Sebastiani M.; Quartuccio L.; Franceschini F.; Sainaghi P.P.; Orsolini G.; De Angelis R.; Naveen R.; Mahidol University
    Objectives: Disease flares in the post-coronavirus disease 2019 (COVID-19) vaccination period represent a prominent concern, though risk factors are poorly understood. We studied these flares among patients with idiopathic inflammatory myopathies (IIMs) and other autoimmune rheumatic diseases (AIRDs). Methods: The COVAD-1 and -2 global surveys were circulated in early 2021 and 2022, respectively, and we captured demographics, comorbidities, AIRDs details, COVID-19 infection history and vaccination details. Flares of IIMs were defined as (a) patient self-reported, (b) immunosuppression (IS) denoted, (c) clinical sign directed and (d) with >7.9-point minimal clinically significant improvement difference worsening of Patient-Reported Outcomes Measurement Information System (PROMIS) PROMISPF10a score. Risk factors of flares were analysed using regression models. Results: Of 15 165 total respondents, 1278 IIMs (age 63 years, 70.3% female, 80.8% Caucasians) and 3453 AIRDs were included. Flares of IIM were seen in 9.6%, 12.7%, 8.7% and 19.6% patients by definitions (a) to (d), respectively, with a median time to flare of 71.5 (10.7-235) days, similar to AIRDs. Patients with active IIMs pre-vaccination (OR 1.2; 95% CI 1.03, 1.6, P = 0.025) were prone to flares, while those receiving rituximab (OR 0.3; 95% CI 0.1, 0.7, P = 0.010) and AZA (OR 0.3, 95% CI 0.1, 0.8, P = 0.016) were at lower risk. Female gender and comorbidities predisposed to flares requiring changes in IS. Asthma (OR 1.62; 95% CI 1.05, 2.50, P = 0.028) and higher pain visual analogue score (OR 1.19; 95% CI 1.11, 1.27, P < 0.001) were associated with disparity between self-reported and IS-denoted flares. Conclusion: A diagnosis of IIMs confers an equal risk of flares in the post-COVID-19 vaccination period to AIRDs, with active disease, female gender and comorbidities conferring a higher risk. Disparity between patient- and physician-reported outcomes represents a future avenue for exploration.
  • No Thumbnail Available
    ItemMetadata only
    The impact of multimorbidity on Quality of Life in inflammatory myopathies: A cluster analysis from the COVAD dataset
    (2025-04-01) Fornaro M.; Venerito V.; Pellico M.R.; Iannone F.; Joshi M.; Chen Y.M.; Tan A.L.; Saha S.; Chatterjee T.; Agarwal V.; Shinjo S.K.; Hoff L.S.; Kadam E.; Ziade N.; Velikova T.; Hasan A.T.M.T.; Shumnalieva R.; Milchert M.; Tan C.L.; Gracia-Ramos A.E.; Cavagna L.; Vaidya B.; Kuwana M.; Shaharir S.S.; Knitza J.; Makol A.; Tehozol E.A.Z.; Serrano J.R.; Halabi H.; Dey D.; Toro-Gutiérrez C.E.; Goo P.A.; Caballero-Uribe C.V.; Distler O.; Katchamart W.; Day J.; Parodis I.; Nikiphorou E.; Chinoy H.; Agarwal V.; Gupta L.; Sen P.; Javaid M.; Andreoli L.; Lini D.; Schreiber K.; Nune A.; Patel A.; Pauling J.D.; Wincup C.; Barman B.; García-De La Torre I.; Colunga-Pedraza I.J.; Merayo-Chalico J.; Chibuzo O.C.; El Kibbi L.; Lilleker J.B.; Salim B.; Gheita T.; Saavedra M.A.; Griger Z.; Kardes S.; Vince M.N.; Singh Y.P.; Ranjan R.; Jain A.; Pandya S.C.; Pilania R.K.; Sharma A.; Manoj M.M.; Gupta V.; Kavadichanda C.G.; Patro P.S.; Ajmani S.; Phatak S.; Goswami R.P.; Chowdhury A.C.; Mathew A.J.; Shenoy P.; Asranna A.; Bommakanti K.T.; Shukla A.; Pande A.R.; Chandwar K.; Ghodke A.; Boro H.; Fazal Z.Z.; Cansu D.Ü.; Yıldırım R.; Gasparyan A.Y.; Del Papa N.; Sambataro G.; Fabiola A.; Govoni M.; Parisi S.; Bocci E.B.; Sebastiani G.D.; Fusaro E.; Sebastiani M.; Quartuccio L.; Fornaro M.; Mahidol University
    Objective: The presence of comorbidities can substantially affect patients’ quality of life, but data regarding their impact on idiopathic inflammatory myopathies (IIMs) are limited. Methods: We examined the prevalence of comorbidities in IIM patients, other autoimmune rheumatic diseases (oAIRDs) and healthy controls (HCs), using data from the self-reported COVAD-2 survey. We defined basic multimorbidity (BM) as the presence of ≥2 non-rheumatic chronic conditions and complex multimorbidity (CM) as the presence of ≥3 non-rheumatic chronic conditions affecting ≥3 organ systems. Hierarchical clustering on principal components was performed for grouping. Results: Among the COVAD respondents, 1558 IIMs, 4591 oAIRDs and 3652 HCs were analysed. IIMs exhibited a high burden of comorbidities (odds ratio [OR]: 1.62 vs oAIRDs and 2.95 vs HCs, P<0.01), BM (OR: 1.66 vs oAIRDs and 3.52 vs HCs, P<0.01), CM (OR: 1.69 vs AIRDs and 6.23 vs HCs, P<0.01) and mental health disorders (MHDs) (OR: 1.33 vs oAIRDs and 2.63 vs HCs, P<0.01). Among the IIM patients, those with comorbidities or MHDs had lower PROMIS Global Physical (PGP), PROMIS Global Mental (PGM), and PROMIS Physical Function (SF10) scores, and higher fatigue (F4a) scores (all P<0.001). PGP, PGM, SF10a and F4a were influenced by age, active disease, BM and MHDs. Four distinct clusters were identified among the IIMs according to comorbidities and PROMIS scores. Conclusion: Patients with IIMs have a higher burden of comorbidities that influence physical and mental health, identifiable as clinical clusters for optimized and holistic management approaches.
  • No Thumbnail Available
    ItemMetadata only
    Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys
    (2023-10-03) Sen P.; Naveen R.; Houshmand N.; Moghadam Kia S.; Joshi M.; Saha S.; Jagtap K.; Agarwal V.; Nune A.; Nikiphorou E.; Tan A.L.; Shinjo S.K.; Ziade N.; Velikova T.; Milchert M.; Parodis I.; Gracia-Ramos A.E.; Cavagna L.; Kuwana M.; Knitza J.; Makol A.; Patel A.; Pauling J.D.; Wincup C.; Barman B.; Zamora Tehozol E.A.; Rojas Serrano J.; García-De La Torre I.; Colunga-Pedraza I.J.; Merayo-Chalico J.; Chibuzo O.C.; Katchamart W.; Akawatcharangura Goo P.; Shumnalieva R.; Chen Y.M.; Hoff L.S.; El Kibbi L.; Halabi H.; Vaidya B.; Sazliyana Shaharir S.; Hasan A.T.M.T.; Dey D.; GutiCrossed D Sign©rrez C.E.T.; Caballero-Uribe C.V.; Lilleker J.B.; Salim B.; Gheita T.; Chatterjee T.; Distler O.; Saavedra M.A.; Day J.; Chinoy H.; Kardes S.; Andreoli L.; Lini D.; Screiber K.; Vince M.N.; Singh Y.P.; Ranjan R.; Jain A.; Pandya S.C.; Pilania R.K.; Sharma A.; Manesh Manoj M.; Gupta V.; Kavadichanda C.G.; Patro P.S.; Ajmani S.; Phatak S.; Goswami R.P.; Chowdhury A.C.; Mathew A.J.; Shenoy P.; Asranna A.; Bommakanti K.T.; Shukla A.; Pande A.R.; Chandwar K.; Ghodke A.; Boro H.; Fazal Z.Z.; Cansu D.Ü.; Ylldlrlm R.; Gasparyan A.Y.; Del Papa N.; Sambataro G.; Fabiola A.; Govoni M.; Parisi S.; Bocci E.B.; Sebastiani G.D.; Fusaro E.; Sebastiani M.; Quartuccio L.; Franceschini F.; Sainaghi P.P.; Orsolini G.; De Angelis R.; Danielli M.G.; Venerito V.; Mahidol University
    OBJECTIVE: COVID-19 vaccines have a favorable safety profile in patients with autoimmune rheumatic diseases (AIRDs) such as idiopathic inflammatory myopathies (IIMs); however, hesitancy continues to persist among these patients. Therefore, we studied the prevalence, predictors and reasons for hesitancy in patients with IIMs, other AIRDs, non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs), using data from the two international COVID-19 Vaccination in Autoimmune Diseases (COVAD) e-surveys. METHODS: The first and second COVAD patient self-reported e-surveys were circulated from March to December 2021, and February to June 2022 (ongoing). We collected data on demographics, comorbidities, COVID-19 infection and vaccination history, reasons for hesitancy, and patient reported outcomes. Predictors of hesitancy were analysed using regression models in different groups. RESULTS: We analysed data from 18 882 (COVAD-1) and 7666 (COVAD-2) respondents. Reassuringly, hesitancy decreased from 2021 (16.5%) to 2022 (5.1%) (OR: 0.26; 95% CI: 0.24, 0.30, P < 0.001). However, concerns/fear over long-term safety had increased (OR: 3.6; 95% CI: 2.9, 4.6, P < 0.01). We noted with concern greater skepticism over vaccine science among patients with IIMs than AIRDs (OR: 1.8; 95% CI: 1.08, 3.2, P = 0.023) and HCs (OR: 4; 95% CI: 1.9, 8.1, P < 0.001), as well as more long-term safety concerns/fear (IIMs vs AIRDs - OR: 1.9; 95% CI: 1.2, 2.9, P = 0.001; IIMs vs HCs - OR: 5.4 95% CI: 3, 9.6, P < 0.001). Caucasians [OR 4.2 (1.7-10.3)] were likely to be more hesitant, while those with better PROMIS physical health score were less hesitant [OR 0.9 (0.8-0.97)]. CONCLUSION: Vaccine hesitancy has decreased from 2021 to 2022, long-term safety concerns remain among patients with IIMs, particularly in Caucasians and those with poor physical function.